Iptacopan NEW
| Price | $132 | $328 | $563 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-13 |
Product Details
| Product Name: Iptacopan | CAS No.: 1644670-37-0 |
| Purity: 99.52% | Supply Ability: 10g |
| Release date: 2024/11/13 |
Product Introduction
Bioactivity
| 名稱 | Iptacopan |
| 描述 | Iptacopan (LNP023) is an inhibitor with high affinity to factor B, with a KD value of 7.9 nM and an IC50 value of 10 nM. |
| 體外活性 | METHODS: Blood from three patients was analyzed in 2-14 replicates and Iptacopan was used at 1 μM. Hemolysis of PNH erythrocytes was determined by FACS analysis. RESULTS LNP023 can block C3 deposition on the surface of CD59-negative red blood cells. [2] |
| 體內(nèi)活性 | METHODS: Iptacopan (LNP023) was tested in KRN-induced arthritis at doses of 20, 60 and 180 mg/kg by injection twice daily. RESULTS Comprehensive disease protection was observed at 60 and 180 mg/kg, and LNP023 significantly inhibited complement activation in joints at all doses, with significant reductions in Ba, C3d, and C5a levels. [1] METHODS: Sixty-eight patients with biopsy-proven C3G, decreased C3 (<77 mg/dl), proteinuria ≥1.0 g/g), and estimated glomerular filtration rate (eGFR) ≥30 ml/min per 1.73 m2 were recruited. Patients will be randomized 1:1 to receive iptacopan 200 mg twice daily or placebo for 6 months, followed by open-label treatment of all patients with iptacopan 200 mg twice daily for 6 months. RESULTS Iptacopan slows disease progression by inhibiting FB and preventing excessive activation of AP and may become one of the first targeted therapies available for C3G patients. [3] |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 55 mg/mL (130.17 mM), Sonication is recommended. |
| 關(guān)鍵字 | LNP 023 | LNP-023 | Iptacopan |
| 相關(guān)庫 | FDA上市及藥典收錄分子庫 | 經(jīng)典已知活性庫 | 上市藥物庫 | 藥物功能重定位化合物庫 | 臨床期小分子藥物庫 | 已知活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $155.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $2380.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-22 | |
| $132.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-13 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY